Clinical Trials Logo

Filter by:
NCT ID: NCT02713282 Completed - Schizophrenia Clinical Trials

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Start date: April 28, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to estimate the proportion of participants fulfilling criteria for symptomatic remission following a transition to 12 months treatment with flexible-dose paliperidone palmitate 3 month formulation (PP3M) in participants with schizophrenia previously adequately treated with paliperidone palmitate 1 month formulation (PP1M) for at least 4 months.

NCT ID: NCT02678312 Completed - Clinical trials for Pediatric Heart Failure

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Start date: November 3, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study consists of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the way the body absorbs, distributes, metabolizes and removes the drug LCZ696. This will help determine the proper dose of LCZ696 for Part 2 of the study. The purpose for Part 2 is to compare the effectiveness and safety of LCZ696 with enalapril in a double-blind manner, in pediatric heart failure patients over 52 weeks of treatment.

NCT ID: NCT02663180 Completed - Depression Literacy Clinical Trials

Effects of an Educational Program on Depression Literacy and Stigma Among Secondary School Students in Jazan City

Start date: January 2016
Phase: N/A
Study type: Interventional

Depression is a serious mental health disease. It is generally characterized by sadness, loss of interest in activities, and decreased energy. Globally, it is estimated that almost 350 million people suffer from depression. In Saudi Arabia, literature suggested that prevalence of depression among boy's secondary school students in Abha city was 38.2%. Another study found that the prevalence of depression was 22.4 % as moderate, 7.3 % as severe and 3.7% as very severe, with a clear predominance prevalence of depression in girls as in boys (1.5 times). It is important to assess depression literacy including knowledge and beliefs about mental disorders among adolescent. A high level of mental health literacy on depression leads to a better understanding and outcomes of depressive disorders. Schools are a typical venue in which to embed mental health literacy because the school students are more familiar with educational activities. Studies concluded that educational intervention about depression literacy and destigmatization improves knowledge and may decrease stigma. Further research, intervention and activism are needed in the field of mental health in Arab countries to improve awareness of mental health problems. Objectives: This study is aimed to measure the effect of educational intervention program about depression among secondary schools in Jazan city on depression literacy and stigma during the academic year 2015-2016. The intervention: the intervention will held at each selected intervention school separately. The program will be over 2 weeks intervention as the following: - Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools. - Contact strategies: the investigators will show a video of a young male who had been diagnosed (i.e., not an actor) with depression. Benefits: * The intervention group will join educational intervention program they expected to benefit from the program through increase their depression literacy and improve depression stigma, and control group will not join any form of intervention. Risk: There is no expected risk for participating in the study. Consent: Three Informed Consents forms will be signed from students, guardians and school manager.

NCT ID: NCT02661217 Completed - Clinical trials for Heart Failure With Reduced Ejection Fraction

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

TRANSITION
Start date: February 12, 2016
Phase: Phase 4
Study type: Interventional

To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with LCZ696 in HFrEF patients following stabilization after an ADHF episode.

NCT ID: NCT02640664 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Rainbow Extension Study

RainbowExt
Start date: June 16, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)

NCT ID: NCT02640196 Completed - Clinical trials for Staff Anaesthesiologists

Videolaryngoscopes for Double Lumen Tube Intubations in Simulated Easy and Difficult Airway

Start date: March 2015
Phase: N/A
Study type: Interventional

The investigators hypothesized that the use of the King Vision™ and the Airtraq® VL would reduce the time to DLT intubation compared with the GlideScope® and Macintosh in simulated easy and difficult airways. The investigators have considered to assess the efficacy of each device in manikins before considering to evaluate them in patients undergoing thoracic procedures. Twenty-one staff anaesthesiologists who had limited prior experience in using the VLs for DLT intubation participated in this randomised crossover study. Following a brief demonstration and two practice attempts, participants were volunteered to insert a DLT using the Macintosh, GlideScope®, Airtraq®, and King Vision™ on two high-fidelity easy and difficult airway simulators in a computer-generated randomized sequence. The primary endpoint, time to DLT intubation, as well as, the views obtained at laryngoscopy, ease of intubation, numbers of laryngoscopy attempts and optimisation manoeuvers, and failure to intubation; defined as an attempt took longer than 150 seconds, were recorded.

NCT ID: NCT02637050 Completed - Clinical trials for Hypertension, Pulmonary

A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries

EMEA CTEPH
Start date: March 3, 2016
Phase:
Study type: Observational

The aim of the registry is the assessment of the diagnosis and treatment of CTEPH (Chronic Thromboembolic Pulmonary Hypertension) in EMEA (Europe/Middle East/Africa) countries.

NCT ID: NCT02631382 Completed - Low Back Pain Clinical Trials

Wet Cupping (AlHijamah); Double Versus Single Cupping Technique

Start date: November 2015
Phase: N/A
Study type: Interventional

Randomized clinical trial to compare the effectiveness and safety of double (traditional) versus single (Asian) cupping techniques in chronic low back pain.

NCT ID: NCT02628938 Completed - Halitosis Clinical Trials

Effect of Miswak and Miswak Extract on Oral Malodor

Start date: March 2014
Phase: Phase 2
Study type: Interventional

The aim of this experiment is to investigate the effect of Miswak on oral malodor and to determine whether this effect -if present- is the result of the mechanical action of Miswak or the chemical effect of its extract

NCT ID: NCT02628132 Completed - Breast Cancer Clinical Trials

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The expression of PD-L1 in breast cancer has been previously demonstrated (Ghebeh et al 2006). In addition, PD-L1 has been shown to work as a "molecular shield", by protecting cancer cells from cytotoxic T-cells and chemotherapy induced apoptosis (Ghebeh et al 2008) suggesting to combine PD-L1 blockade with chemotherapy. This trial will test Durvalumab in combination with Paclitaxel on metastatic triple-negative breast cancer patients. The safety profile of Durvalumab as a monotherapy has been previously established (lu et al 2015). In this trial the safety profile and tolerability of Durvalumab given in combination of Paclitaxel will be tested. In addition, the efficacy of this combination on metastatic breast cancer will be monitored.